Navigation Links
Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
Date:9/2/2010

SAN DIEGO, Sept. 2 /PRNewswire/ -- Results from studies related to Optimer Pharmaceuticals, Inc.'s (Nasdaq: OPTR) lead developmental product candidate, fidaxomicin, will be presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held at the Boston Convention and Exhibition Center in Boston on September 12-15, 2010.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Fidaxomicin abstracts and speakers include:"Randomized Controlled Trial (RCT) of Fidaxomicin (FDX) Versus Vancomycin (VAN) in Treatment of Recurrent Clostridium difficile Infection (CDI)"Oral Presentation: Oliver Cornely, M.D.

Tuesday, September 14, 2010 9:00 am - 9:15 am Eastern Time

Presentation number: L1-1305 in 253A

"Clostridium difficile Strain Type as Determined by Restriction Endonuclease Analysis (REA) Typing in Two Phase III Trials of Fidaxomicin vs Vancoymcin: Treatment Outcome for the Epidemic BI/NAP1/027 Strain"Oral Presentation: Dale N. Gerding, M.D.

Tuesday, September 14, 2010 9:15 am - 9:30 am Eastern Time

Presentation number: L1-1306 in 253A

"Correlation of the ATLAS Bedside Scoring System And Its Components With Cure and Recurrence of Clostridium difficile Infection (CDI)"Poster Presentation: Mark A. Miller, M.D.

Tuesday, September 14, 2010 11:15 am - 1:15 pm Eastern Time

Presentation number: K-1692 in Exhibit Hall B1

"Use of Concomitant Antibiotics (CA) Has a Deleterious Effect on Outcomes During Treatment for Clostridium difficile Infection (CDI)"Poster Presentation: Kate Mullane, M.D.

Tuesday, September 14, 2010 11:15 am - 1:15 pm Eastern Time

Presentation number: K-1695 in Exhibit Hall B1

"Comparative Susceptibilities of Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence and Failure from Patients in a Phase III trial (004) of C difficile infection (CDI)"Poster Presentation: Ellie J. Goldstein, M.D.

Tuesday, September 14, 2010 11:15 am - 1:15 pm Eastern Time

Presentation number: K-1691 in Exhibit Hall B1

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).  In two Phase 3 trials completed by Optimer to study the safety and efficacy of fidaxomicin for the treatment of CDI, fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurrence within four weeks of completing therapy) as well as statistically superior in reducing recurrences of CDI by up to 50% when compared with vancomycin, the only FDA approved product for CDI. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea.  Optimer has also successfully completed two Phase 3 trials with Pruvel.  Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
2. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
3. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
4. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
5. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
6. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
7. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
8. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
9. Pfizer to Acquire FoldRx Pharmaceuticals
10. Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China
11. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 12, 2017   Divoti USA will engrave ... the standard of the latest FDA requirements, which stipulates new criteria ... Anyone in need of Medical ID jewelry such as Medical ID ... are engraved in terms of the new FDA requirements . ... Divoti offers this dark mark ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... Miramar, FL (PRWEB) , ... October 12, 2017 ... ... is presenting the latest in wound care advancements to physician colleagues, skilled nursing ... lecture is titled, "Navigating the Treacherous Waters of Wound Care." , "At many ...
Breaking Medicine News(10 mins):